Clinical Trials on Hepatitis C in South Africa

Total 274 results

Kirby Institute

Recruiting

Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir (STRIVE-4)

Hepatitis C

Australia
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
Kirby Institute

Completed

A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams (TEMPO)

Hepatitis C

Australia
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
Bristol-Myers Squibb

Completed

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

Hepatitis C Virus

Australia, United States, Canada, France, Denmark, Italy
Prisma Health-Upstate

Completed

HCV-Smoking Cessation Study

Smoking Cessation | Hepatitis C

United States
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Hepatitis C

United States, Australia, France, Japan, Spain, Sweden, Canada, Germany, Mexico, Denmark, Italy, Korea, Republic of, Taiwan, Argentina, Brazil, Ireland, Poland, Puerto Rico, United Kingdom
Kirby Institute
Flinders University; South Australian Health and Medical Research Institute

Recruiting

Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination (SCALE-C)

Liver Diseases | Digestive System Diseases | RNA Virus Infections | Hepatitis | Hepatitis, Viral, Human | Hepatitis C

Australia
Bristol-Myers Squibb

Completed

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients (HEPCAT)

Hepatitis C Virus

Australia, Sweden, United States, Canada, France, Germany, Denmark, Mexico, Italy, Puerto Rico, Egypt
Kirby Institute

Completed

DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral) (DARE-C II)

Hepatitis C

Australia, New Zealand
Hoffmann-La Roche

Completed

A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

Hepatitis C, Chronic

United States, Canada, Australia, France, Germany, Austria, Italy
Kirby Institute

Not yet recruiting

The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset

Hepatitis C

Australia
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease (SOF/VEL ESRD)

Chronic Hepatitis C

Israel, United Kingdom, Australia, Spain, Canada, New Zealand
Hoffmann-La Roche

Completed

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

Hepatitis C, Chronic

United States, Canada
Kirby Institute

Completed

Surveillance and Treatment of Prisoners With Hepatitis C (SToP-C)

Hepatitis C

Australia
Gilead Sciences

Completed

Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Hepatitis C Virus Infection

Germany, United States, Australia, United Kingdom, Canada, France, New Zealand
Hoffmann-La Roche

Completed

A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

United States, Spain, France, Canada, Germany, Austria, Australia, Brazil, United Kingdom, Italy, Mexico, Poland, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

Hepatitis C, Chronic

United States, Canada, Slovakia, Poland, New Zealand, France, Australia
Kirby Institute

Terminated

Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs (DARLO-C)

Hepatitis C

Australia
Human Genome Sciences Inc.

Completed

A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

Canada, Australia, Israel, Germany, Czech Republic, France, Poland, Romania
Kirby Institute

Recruiting

The National Australian HCV Point-of-Care Testing Program - Minimal Dataset

Hepatitis C

Australia
Hoffmann-La Roche

Completed

A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

Hepatitis C, Chronic

France, Spain, United States, Germany, Canada, Australia, Austria, United Kingdom, Puerto Rico, Italy
Gilead Sciences

Completed

Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

Hepatitis C Virus

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants

Hepatitis B | Pertussis | Tetanus | Diphtheria | Polio | Human Immunodeficiency Virus Infection

South Africa
Gilead Sciences
Quintiles, Inc.

Completed

Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection (QUANTUM)

Hepatitis C, Chronic

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV

Hepatitis B | Pertussis | Diphtheria | Polio | Haemophilus Influenzae Type b

South Africa
Kirby Institute

Recruiting

Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs (TOPIC)

Hepatitis C | Liver Cirrhoses | Liver Inflammation

Australia
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Hepatitis C, Chronic

United States, Australia, United Kingdom, Germany, France, Spain, Belgium, Netherlands, Canada, Brazil, Puerto Rico, Poland, Sweden, Switzerland, Israel
Sanofi

Completed

Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine

Hepatitis B | Whooping Cough | Tetanus | Diphtheria | Poliomyelitis

South Africa
Novartis Pharmaceuticals

Terminated

3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study

Hepatitis C, Chronic

Romania, Italy, Germany, Belgium, Spain, Australia, Thailand, United States, Hungary, Taiwan, Poland, Canada, Puerto Rico, Vietnam, Korea, Republic of, India
Gilead Sciences

Completed

Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6 (ATOMIC)

Hepatitis C, Chronic

United States, Puerto Rico
Hoffmann-La Roche

Completed

Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

Hepatitis C, Chronic

United States
Kirby Institute
National Institutes of Health (NIH); The University of New South Wales

Completed

Australian Trial in Acute Hepatitis C

Hepatitis C

Australia
SciClone Pharmaceuticals

Completed

Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Hepatitis C | Hepatitis C, Chronic

United States, Puerto Rico
Gilead Sciences

Completed

Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study

Hepatitis C Virus Infection

United States, New Zealand, Puerto Rico, Australia
Hoffmann-La Roche

Terminated

An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens

Hepatitis C, Chronic

France, United States, Canada, New Zealand, Spain, Germany, United Kingdom, Australia, Italy, Brazil, Mexico, Slovakia, Poland, Puerto Rico, Austria
Macfarlane Burnet Institute for Medical Research...

Recruiting

Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)

Hepatitis C

Australia
Bristol-Myers Squibb

Completed

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment (HEPCAT)

Hepatitis C Virus

Australia, France, Mexico, United States, Canada, Germany, Denmark, Italy, Puerto Rico, Sweden, Argentina
Medical University of South Carolina

Completed

LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients

Hepatitis C

United States
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis

Hepatitis C

France, Australia
Bristol-Myers Squibb

Completed

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) (Hallmark DUAL)

Hepatitis C Virus

France, Germany, Korea, Republic of, Spain, Taiwan, United States, Canada, Australia, Russian Federation, Austria, Israel, Italy, Netherlands, Argentina, Poland, United Kingdom, Ireland, New Zealand
Prisma Health-Upstate
Albert Einstein College of Medicine; Clemson University

Completed

Intensive Models of HCV Care for Injection Drug Users

Hepatitis C | Medication Adherence

United States
Hoffmann-La Roche

Completed

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

Hepatitis C, Chronic

France, Germany, United States, Spain, Canada, Austria, United Kingdom, Puerto Rico, Italy, Brazil, Mexico
Kirby Institute

Active, not recruiting

Control and Elimination Within Australia of Hepatitis C From People Living With HIV (CEASE)

Hepatitis C | HIV | HIV-HCV Coinfection

Australia
Kirby Institute

Recruiting

The National Australian HCV Point-of-Care Testing Program

Hepatitis C

Australia
Gilead Sciences

Completed

A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Chronic Hepatitis C | Human Immunodeficiency Virus

France, Italy, United Kingdom, Germany, Spain, Australia
Tibotec BVBA
Tibotec Pharmaceutical Limited

Completed

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Hepatitis C, Chronic

United States, Australia, France, United Kingdom, Germany, Spain, Belgium, Israel, Canada, Brazil, Austria, Poland, Netherlands, Sweden, Switzerland, Puerto Rico
Boehringer Ingelheim

Completed

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Hepatitis C, Chronic

United States, Australia, Belgium, Canada, France, Germany, Greece, Italy, New Zealand, Portugal, Spain, United Kingdom
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 (PRINCIPAL)

Hepatitis C Virus (HCV)

Australia, Belgium, France, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Taiwan, United States, Chile, Hong Kong, Argentina, Netherlands, United Kingdom, Singapore, New Zealand, Finland, Greece
Gilead Sciences

Completed

Gilead Sustained Virologic Response (SVR) Registry

Hepatitis C, Chronic

United States, Spain, Netherlands, France, Australia, Canada, Italy, Germany, New Zealand, Belgium, Sweden, United Kingdom, Estonia, Puerto Rico, Austria, Poland, Czechia

Clinical Trials on Hepatitis C in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations